Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bactogard is an anti-infective medication developed and marketed by Indoco Remedies. Its active ingredient is cefpodoxime proxetil, a third-generation oral cephalosporin antibiotic. It functions by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), which prevents the cross-linking of peptidoglycan, leading to bacterial cell lysis. Bactogard is indicated for a wide range of bacterial infections, including acute otitis media, pharyngitis, tonsillitis, sinusitis, skin and soft tissue infections, respiratory tract infections (such as pneumonia and bronchitis), urinary tract infections, and typhoid fever. It is available in various oral formulations, including tablets, suspensions, and drops, making it suitable for both adult and pediatric populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bactogard.